Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case–control study

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 6, 2015, Pages 1201-1205

  Eliakim Raz, N ^a,b   Fishman, G ^a   Yahav, D ^a,b   Goldberg, E ^a,b   Stein, G Y ^a,b   Zvi, H B ^a   Barsheshet, A ^a,b   Bishara, J ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ADULT; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTIONS; COMPLICATION; DIABETES COMPLICATIONS; DIARRHEA; FEMALE; HEART FAILURE; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIABETES COMPLICATIONS; DIARRHEA; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84939972068     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2348-3     Document Type: Article

References (35)

1. Kelly CP, Pothoulakis C, LaMont JT (1994) Clostridium difficile colitis. N Engl J Med 330:257–262
2. Dallal RM, Harbrecht BG, Boujoukas AJ et al (2002) Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:363–372
3. Barbut F, Petit JC (2001) Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 7:405–410
4. Trudel JL (2007) Clostridium difficile colitis. Clin Colon Rectal Surg 20:13–17
5. Pépin J, Valiquette L, Alary ME et al (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472
6. McDonald LC, Killgore GE, Thompson A et al (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353:2433–2441
7. Spencer RC (1998) Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 41(Suppl C):5–12
8. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34:346–353
9. Swindells J, Brenwald N, Reading N, Oppenheim B (2010) Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol 48(2):606–608
10. Thomas C, Stevenson M, Riley TV (2003) Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 51:1339–1350
11. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC (2006) Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 24:613–619
12. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S (2004) Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 38:475–483
13. Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA (2011) Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 39(3):194–198
14. Chang JY, Antonopoulos DA, Kalra A et al (2008) Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197(3):435–438
15. Larsen N, Vogensen FK, van den Berg FWJ et al (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2):e9085
16. Wu X, Ma C, Han L et al (2010) Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61(1):69–78
17. Cusi K, DeFronzo RA (1998) Metformin: a review of its metabolic effects. Diabetes Rev 6:89–131
18. Karlsson FH, Tremaroli V, Nookaew I et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498(7452):99–103
19. Shin NR, Lee JC, Lee HY et al (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63(5):727–735
20. Charlson ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
21. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ 171:33–38
22. Qu HQ, Jiang ZD (2014) Clostridium difficile infection in diabetes. Diabetes Res Clin Pract 105(3):285–294
23. Sullivan A, Edlund C, Nord CE (2001) Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1:101–114
24. Manges AR, Labbe A, Loo VG et al (2010) Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202:1877–1884
25. Hopkins MJ, Macfarlane GT (2002) Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51:448–454
26. Bishara J, Farah R, Mograbi J et al (2013) Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 57(4):489–493
27. Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanisms of action of metformin: old or new insights? Diabetologia 56(9):1898–1906
28. Burcelin R (2014) The antidiabetic gutsy role of metformin uncovered? Gut 63(5):706–707
29. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510(7506):542–546
30. Derrien M, Vaughan EE, Plugge CM, de Vos WM (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54:1469–1476
31. Belzer C, de Vos WM (2012) Microbes inside—from diversity to function: the case of Akkermansia. ISME J 6(8):1449–1458
32. Everard A, Belzer C, Geurts L et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110(22):9066–9071
33. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334(9):574–579
34. Harrigan RA, Nathan MS, Beattie P (2001) Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 38(1):68–78
35. Lysy J, Israeli E, Goldin E (1999) The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol 94(8):2165–2170